Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin.
The topoisomerase I inhibitor, 9-nitro-camptothecin (9NC), is highly tumoricidal against glioblastoma multiforme (GBM) in vitro. However, systemic administration of 9NC has not shown the expected efficacy in clinical trials. This failure may be due to the rapid hydrolysis of 9NC in plasma from the active form to the inactive and myelosuppressive form in the presence of human albumin at physiologic pH. Concurrent treatment with anticonvulsants and dexamethasone, drugs indispensable for the supportive therapy of patients with GBM, has also been shown to decrease plasma concentrations of these drugs. Intrathecal drug delivery circumvents the blood-brain barrier and minimizes systemic toxicity. Intrathecal delivery of 9NC may also have the more specific advantage of significantly reducing the hydrolysis of 9NC that occurs after systemic delivery due to the more favorable pH and reduced albumin content in cerebrospinal fluid. The present study evaluated the toxicity and efficacy of intrathecal delivery of 9NC in an athymic rat model of neoplastic meningitis. Toxicity tests showed that 0.3 micromol (5000 microM), 0.03 micromol (500 microM), 0.003 micromol (50 microM), or 0.0003 micromol (5 microM) of 9NC administered intrathecally to the athymic rats caused no evidence of clinical or histological toxicity. Intrathecal administration of 0.3 micromol (5000 microM) of 9NC twice a week for three doses to athymic rats with neoplastic meningitis induced by the GBM cell line, U87MGDeltaEGFR, resulted in a 26% increase of median survival compared to the control group (p < 0.005). These results suggest that intrathecal treatment with 9NC may be useful for patients with GBM neoplastic meningitis.
Ochiai
Hidenobu
H
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA. hochiai@fc.miyazaki-u.ac.jp
Pernell
Chris T
CT
Archer
Gary E
GE
Chewning
Tracy A
TA
McLendon
Roger E
RE
Friedman
Henry S
HS
Sampson
John H
JH
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004195:Disease Models, Animal; D005909:Glioblastoma / Q000150:complications* / Q000188:drug therapy*; D007278:Injections, Spinal; D008581:Meningitis / Q000188:drug therapy* / Q000209:etiology*; D051381:Rats; D011923:Rats, Nude
D000970:Antineoplastic Agents; C079905:rubitecan; D002166:Camptothecin